A study to evaluate the dose-exposure, safety, and exploratory efficacy of nerandomilast in children and adolescents from 2 years to less than 18 years of age with fibrosing interstitial lung disease (Part A: double-blind, placebo-controlled in children from 6 to less than 18 years of age and open-label active treatment in children from 2 to less than 6 years of age), followed by an open-label phase with active treatment (Part B).

• Código protocolo: 1305-0022
• Código EudraCT: _
• Patología: Tumors
• Investigador/a principal:  Torrent Vernetta, Alba
• Grupo de investigación:  Creixement i desenvolupament
• Servicio: Pediatria General i Especialitats
• Fase: Fase III
• Reclutamiento: Cerrado
• Estado: Iniciat